[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.187.2. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
The World in Medicine
July 15, 2009

Treating Multidrug-Resistant TB

JAMA. 2009;302(3):246. doi:10.1001/jama.2009.1015

A new drug with a novel mechanism of action against tuberculosis infection shows promise for treating multidrug-resistant tuberculosis (MDR-TB), according to interim results in an ongoing phase 2, randomized placebo-controlled trial conducted by an international team of researchers (Diacon AH et al. N Engl J Med. 2009;360[23]:2397-2405).

The drug, TMC207, is a diarylquinoline that inhibits the enzyme adenosine triphosphate (ATP) synthase, disrupting the production of ATP, the molecule that serves as the energy currency of cells.

First Page Preview View Large
First page PDF preview
First page PDF preview
×